The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents. Selective Melanocortin-4 (MC4R) ...
Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. The deal will see Superluminal use its GPCR platform ...
Superluminal and Eli Lilly collaborate to develop small molecule therapeutics targeting GPCRs for cardiometabolic diseases and obesity. Superluminal's AI-driven platform integrates structural biology, ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
FUJISAWA, Japan & BOSTON, June 24, 2025--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate ...
Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by ...
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Superluminal Medicines, Inc., “The Membrane Company” using generative biology, chemistry, and machine learning approaches to revolutionize the speed and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results